A $2.1 billion funding round fuels Isomorphic Labs as it deploys its new Drug Design Engine. The Google DeepMind spinout partnered with Novartis and Eli Lilly to identify hidden drug targets. This shift from protein prediction to active discovery aims to move AI-designed medicines past the testing bottleneck and into clinical use.